Tudor Investment Corp ET AL Sells 109,061 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Tudor Investment Corp ET AL cut its stake in 10x Genomics, Inc. (NASDAQ:TXG) by 35.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 200,011 shares of the company’s stock after selling 109,061 shares during the quarter. Tudor Investment Corp ET AL owned about 0.17% of 10x Genomics worth $2,872,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in TXG. Assenagon Asset Management S.A. purchased a new position in 10x Genomics in the fourth quarter worth $26,308,000. ARK Investment Management LLC grew its stake in 10x Genomics by 11.1% during the 4th quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company’s stock worth $171,517,000 after buying an additional 1,193,712 shares during the last quarter. SVB Wealth LLC acquired a new position in 10x Genomics during the 4th quarter valued at about $7,505,000. Trexquant Investment LP raised its stake in 10x Genomics by 196.2% in the fourth quarter. Trexquant Investment LP now owns 594,611 shares of the company’s stock valued at $8,539,000 after buying an additional 393,854 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in 10x Genomics in the fourth quarter worth about $5,557,000. 84.68% of the stock is owned by institutional investors.

10x Genomics Trading Up 4.1 %

Shares of TXG opened at $8.43 on Friday. The firm has a market cap of $1.03 billion, a P/E ratio of -5.55 and a beta of 2.01. 10x Genomics, Inc. has a 12 month low of $6.78 and a 12 month high of $28.25. The stock’s 50 day moving average is $9.17 and its two-hundred day moving average is $12.81.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. Equities research analysts forecast that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Insider Buying and Selling

In related news, insider Benjamin J. Hindson sold 4,573 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the transaction, the insider now directly owns 335,324 shares of the company’s stock, valued at approximately $3,712,036.68. This represents a 1.35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Serge Saxonov sold 5,092 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $56,368.44. Following the sale, the chief executive officer now directly owns 879,482 shares of the company’s stock, valued at $9,735,865.74. The trade was a 0.58 % decrease in their position. The disclosure for this sale can be found here. Insiders own 10.03% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on TXG. UBS Group decreased their price objective on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. JPMorgan Chase & Co. lowered their price objective on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a research report on Thursday, April 24th. Leerink Partnrs cut 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. Finally, Leerink Partners lowered 10x Genomics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $25.00 to $12.00 in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $18.85.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.